在多塞塔塞尔诱导的神经病症中使用孟坦丁预防:乳腺癌随机临床试验
Pegah Mohammadzadeh1, Elnaz Shaseb2, Zohreh Sanaat1
1Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran (the Islamic Republic of).
BMJ supportive & palliative care
|September 22, 2025
概括
孟坦丁可以帮助预防乳腺癌患者的多塞塔塞尔诱导的外周神经病变. 这项研究发现,在服用孟坦丁的患者中,神经病变症状较少,这表明它作为预防性治疗的潜力.
科学领域:
- 在瘤学瘤学.
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 周围神经病变是一种常见的,限制剂量的一种Taxane化疗的副作用.
- 多塞塔克塞尔是一种常见的纳税素,在乳腺癌患者中经常引起外围神经病变.
- 化学疗法诱导的外周神经病变 (CIPN) 的有效预防策略对于维持治疗坚持和生活质量至关重要.
研究的目的:
- 评估孟坦丁在预防乳腺癌患者的多塞塔塞尔诱导的外周神经病变方面的疗效.
- 评估孟坦因对神经病症症状和患者报告结果的影响.
- 为了确定孟坦能否降低多塞塔克塞尔治疗期间神经病变的发生率或严重程度.
主要方法:
- 一项随机临床试验,涉及40名患有非转移性乳腺癌的女性 (18-64岁),接受AC-T疗法 (包括多塞塔塞尔).
- 干预组每天接受20毫克的孟坦丁,持续8周,从第一个多塞塔塞尔周期开始.
- 在基线和启动后1,3个月和6个月使用Douleur神经病变4 (DN4) 和常见术语对不良事件的标准 (CTCAE) 评估神经病变.
主要成果:
- 记忆素组在1个月 (p=0.033) 和3个月 (p<0.001) 的随访中显示出明显较低的DN4得分.
- 在记忆剂和对照组之间,神经病变的持续时间和发病时间显著不同 (分别为p=0.050和p=0.001).
- 值得注意的是,在记忆剂组中,40%的患者没有出现神经病变,而对照组的患者只有10%.
结论:
- 孟坦丁20毫克/天在降低乳腺癌患者的多塞塔塞尔诱导的外周神经病变风险方面显示出潜在的有效性.
- 这些发现表明,孟坦因可能是治疗化疗诱导的外围神经病变的可行预防方案.
- 需要进一步的研究来证实这些初步发现,并确定美曼在CIPN预防中的作用.
关键词:
乳房 乳房 乳房相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
589
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
589
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
605
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
605
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
815
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
815
Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
676
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
676
Alzheimer's Disease: Treatment
825
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
825


